Cargando…

Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study

OBJECTIVE: Switching from mepolizumab to benralizumab has been reported to significantly improve both asthma control and the lung function. However, the data on its efficacy in elderly patients with severe eosinophilic asthma are limited. This study aimed to assess whether elderly patients with seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Isoyama, Shoko, Ishikawa, Nobuhisa, Hamai, Kosuke, Matsumura, Mirai, Kobayashi, Hiroki, Nomura, Akio, Ueno, Sayaka, Tanimoto, Takuya, Maeda, Hiroyuki, Iwamoto, Hiroshi, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259321/
https://www.ncbi.nlm.nih.gov/pubmed/35650114
http://dx.doi.org/10.2169/internalmedicine.8180-21
_version_ 1784741752368791552
author Isoyama, Shoko
Ishikawa, Nobuhisa
Hamai, Kosuke
Matsumura, Mirai
Kobayashi, Hiroki
Nomura, Akio
Ueno, Sayaka
Tanimoto, Takuya
Maeda, Hiroyuki
Iwamoto, Hiroshi
Hattori, Noboru
author_facet Isoyama, Shoko
Ishikawa, Nobuhisa
Hamai, Kosuke
Matsumura, Mirai
Kobayashi, Hiroki
Nomura, Akio
Ueno, Sayaka
Tanimoto, Takuya
Maeda, Hiroyuki
Iwamoto, Hiroshi
Hattori, Noboru
author_sort Isoyama, Shoko
collection PubMed
description OBJECTIVE: Switching from mepolizumab to benralizumab has been reported to significantly improve both asthma control and the lung function. However, the data on its efficacy in elderly patients with severe eosinophilic asthma are limited. This study aimed to assess whether elderly patients with severe eosinophilic asthma could experience an improved asthma control and lung function when switching directly from mepolizumab to benralizumab. METHODS: In this single-center, retrospective study conducted between February 2017 and September 2018, we assessed the effect of switching the treatment directly from mepolizumab to benralizumab on eosinophil levels, exacerbation rates, and lung function. We compared the treatment responses between the two groups using either Fisher's exact test or Mann-Whitney U-test, as appropriate. PATIENTS: We enrolled 12 elderly patients (age ≥65 years) with severe eosinophilic asthma treated with mepolizumab at Hiroshima Prefectural Hospital (Hiroshima, Japan) during the study period. Six patients were switched from mepolizumab to benralizumab, and six continued with the mepolizumab treatment. RESULTS: The switch from mepolizumab to benralizumab caused a near-complete reduction in the eosinophil count (p=0.008). The annual rate of clinically relevant exacerbations and hospitalizations diminished as well, albeit with no statistical significance. We found no improvement in the lung function after switching treatment and no difference in the treatment response between the groups. CONCLUSION: Although this study is based on a small sample of participants, the results indicate that both mepolizumab treatment and switching from mepolizumab to benralizumab treatment without a washout period have clinically relevant asthma control benefits for elderly patients with severe eosinophilic asthma.
format Online
Article
Text
id pubmed-9259321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-92593212022-07-19 Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study Isoyama, Shoko Ishikawa, Nobuhisa Hamai, Kosuke Matsumura, Mirai Kobayashi, Hiroki Nomura, Akio Ueno, Sayaka Tanimoto, Takuya Maeda, Hiroyuki Iwamoto, Hiroshi Hattori, Noboru Intern Med Original Article OBJECTIVE: Switching from mepolizumab to benralizumab has been reported to significantly improve both asthma control and the lung function. However, the data on its efficacy in elderly patients with severe eosinophilic asthma are limited. This study aimed to assess whether elderly patients with severe eosinophilic asthma could experience an improved asthma control and lung function when switching directly from mepolizumab to benralizumab. METHODS: In this single-center, retrospective study conducted between February 2017 and September 2018, we assessed the effect of switching the treatment directly from mepolizumab to benralizumab on eosinophil levels, exacerbation rates, and lung function. We compared the treatment responses between the two groups using either Fisher's exact test or Mann-Whitney U-test, as appropriate. PATIENTS: We enrolled 12 elderly patients (age ≥65 years) with severe eosinophilic asthma treated with mepolizumab at Hiroshima Prefectural Hospital (Hiroshima, Japan) during the study period. Six patients were switched from mepolizumab to benralizumab, and six continued with the mepolizumab treatment. RESULTS: The switch from mepolizumab to benralizumab caused a near-complete reduction in the eosinophil count (p=0.008). The annual rate of clinically relevant exacerbations and hospitalizations diminished as well, albeit with no statistical significance. We found no improvement in the lung function after switching treatment and no difference in the treatment response between the groups. CONCLUSION: Although this study is based on a small sample of participants, the results indicate that both mepolizumab treatment and switching from mepolizumab to benralizumab treatment without a washout period have clinically relevant asthma control benefits for elderly patients with severe eosinophilic asthma. The Japanese Society of Internal Medicine 2022-06-01 2022-06-01 /pmc/articles/PMC9259321/ /pubmed/35650114 http://dx.doi.org/10.2169/internalmedicine.8180-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Isoyama, Shoko
Ishikawa, Nobuhisa
Hamai, Kosuke
Matsumura, Mirai
Kobayashi, Hiroki
Nomura, Akio
Ueno, Sayaka
Tanimoto, Takuya
Maeda, Hiroyuki
Iwamoto, Hiroshi
Hattori, Noboru
Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
title Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
title_full Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
title_fullStr Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
title_full_unstemmed Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
title_short Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
title_sort switching treatment from mepolizumab to benralizumab for elderly patients with severe eosinophilic asthma: a retrospective observational study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259321/
https://www.ncbi.nlm.nih.gov/pubmed/35650114
http://dx.doi.org/10.2169/internalmedicine.8180-21
work_keys_str_mv AT isoyamashoko switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT ishikawanobuhisa switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT hamaikosuke switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT matsumuramirai switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT kobayashihiroki switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT nomuraakio switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT uenosayaka switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT tanimototakuya switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT maedahiroyuki switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT iwamotohiroshi switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy
AT hattorinoboru switchingtreatmentfrommepolizumabtobenralizumabforelderlypatientswithsevereeosinophilicasthmaaretrospectiveobservationalstudy